FDA approves trifluridine-tipiracil for metastatic gastric cancer


  • Jim Kling
  • Oncology drug update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The combination of trifluridine and tipiracil, previously approved by the FDA for advanced colorectal cancer, has been approved for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • The indication includes patients previously treated with ≥2 chemotherapy regimens that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Why this matters

  • There are few therapeutic options for these patients after failure of first-line therapy.

Key points

  • The approval is based on results from the phase 3 TAGS trial, which randomly assigned 507 patients in 17 countries and 110 sites to receive either trifluridine/tipiracil or placebo.
  • Survival was better in the treatment group (5.7 vs 3.6 months; HR, 0.69; 1-sided P=.00029; 2-sided P=.00058).
  • 80% of patients in the treatment group experienced grade 3 or worse adverse events compared with 58% in the placebo group.
  • Neutropenia occurred in 34% and anemia occurred in 19% of the treatment group.
  • 43% of patients in the treatment group had a serious adverse event of any cause compared with 42% of the placebo group.

Prescribing information, click here.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit